Affiliation: Harvard University
- Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vectorToshihiko Kuroda
Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 66:10127-35. 2006..Our results suggest that a transcriptionally regulated oncolytic herpes vector targeting beta-catenin/Tcf signal is very efficacious against CRC tumors carrying an APC gene mutation between the first and second 20-amino-acid repeats...
- Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumorsTa-Chiang Liu
Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Clin Cancer Res 12:6791-9. 2006..This strategy can be applied to other oncolytic viruses and for clinical translation...
- Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacyTa-Chiang Liu
Molecular Neurosurgery Laboratory, Massachusetts General Hospital and Harvard Medical School, CPZN-3800 Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
Mol Ther 14:789-97. 2006..Enhancing the antiangiogenic properties of oncolytic HSV through the expression of antiangiogenic factors such as PF4 is a powerful new strategy that targets both the tumor cells and tumor vasculature...
- Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinasesToshihiko Kuroda
Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
BMC Biotechnol 6:40. 2006..coli. Thus, we sought a method to generate recombinant oncolytic HSV vectors more easily and quickly using BAC technology...
- Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectorsHiroaki Wakimoto
Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
Cancer Res 69:3472-81. 2009..This is important for designing new oHSV vectors and clinical trials. Moreover, the new glioma models described in this study provide powerful tools for testing experimental therapeutics and studying invasion and angiogenesis...
- Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumorsKaoru Tamura
Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA
Mol Ther 21:68-77. 2013..This study sheds new light on the mechanism by which oHSV and TRAIL function in concert to overcome therapeutic-resistance, and provides an oncolytic virus based platform to target a broad spectrum of different cancer types...
- Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated systemHiroshi Fukuhara
Molecular Neurosurgery Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA
Cancer Res 65:10663-8. 2005..The results show that "arming" with multiple transgenes can improve the efficacy of oncolytic HSV-1 vectors. The use of our system may facilitate the development and testing of various armed oncolytic HSV-1 vectors...
- Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their constructionDeva S Jeyaretna
Massachusetts General Hospital, Molecular Neurosurgery Laboratory, Department of Neurosurgery, Boston, MA 02114, USA
Curr Opin Mol Ther 9:447-66. 2007..This review discusses the current state of research into the development of oncolytic HSV-1 vectors, and highlights the promise that armed oncolytic HSV-1 vectors might hold for the future...